Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: OTC vaginal contraceptives

This article was originally published in The Tan Sheet

Executive Summary

OTC vaginal contraceptives: Sen. Patty Murray (D-Wash.) and Reps. Connie Morella (R-Md.) and Nita Lowey (D-N.Y.) oppose FDA's proposed rule to require NDAs for OTC vaginal contraceptives in a June 30 letter to FDA Commissioner David Kessler. "We believe the government should be encouraging the development of new contraceptive products and expanding women's reproductive choice, not discouraging businesses from manufacturing existing products that have been shown to be safe and effective," they said. Industry also has strongly opposed the FDA proposal ("The Tan Sheet" June 19, pp. 9-12)...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts